SUBJECT INDEX

ABO incompatibility
A₂ to O donors, 28, 427
graft survival, 28
acetate dialysis
acetate kinetics during dialysis, 340
effect on complement, 159
left ventricular function, 281
respiratory response, 334
results of EEG monitoring, 351
acidosis
association with bone histology, 191
correction limited by potassium removal, 366
acute post-streptococcal glomerulonephritis, rheumatoid factor deposition, 686
acute renal failure
see renal failure, acute
acyclovir, treatment in herpes infections, 520
adenoviruses, 523
adrenaline, effect on potassium metabolism, 756
adrenergic receptors
effect on potassium metabolism, 756
in experimental acute uraemia, 788
on platelets of haemodialysis patients, 270
alanine aminotransferase, elevation in haemodialysis patients, 153
aldosterone
in hypertension, 697
in nephrotic syndrome, 738
allograft
see transplantation, rejection
aluminium
associated bone disease, 195, 203
celation therapy, 203
effect of CaCO₃, 784
effect on parathyroid hormone, 226, 244
estimation in bone, 205
aluminium (continued)
histological identification in bone biopsies, 196, 250
in patients with idiopathic hypercalcaemia, 248
relationship to encephalopathy, 45
water treatment by deionisation, 204
amino acids
supplements in uraemia, 773
therapy in acute renal failure, 131
aminophylline, effect on suppressor T-cells, 473
antithymocyte globulin
see antilymphocyte globulin
ankylosing spondylitis, association with mesangial IgA disease, 667
antigen reactive cell opsonisation, 411
antilymphocyte globulin
association with viral infections, 516
relation to cytomegalovirus infection, 558
apoprotein
effect of carnitine therapy, 302
in haemodialysis and transplant patients, 505
arteriography, intravenous in hypertension, 749
arteriovenous fistulae
see vascular access
artificial beta cell, use in maintaining normoglycaemia in haemodialysis patients, 769
Aspergillus infections, 518
atherosclerosis
incidence in haemodialysis patients, 168
risk factor, 173
autoantibodies in glomerulonephritis, 619
autoantigens in glomerulonephritis, 619
auto-anti-idiotyp antibodies, 412
autonomic nervous system, effects of experimental acute uraemia, 788
B-cell alloantigen, in transplant, 464
beta adrenergic modulation, effect on potassium metabolism, 756
bicarbonate dialysis
effect on complement, 159
effects of pH, 346
left ventricular function, 281
registry data, 38
respiratory response, 334
results of EEG monitoring, 351
blood group antigens
A₂ donors to O recipients, 427
effect on transplant, 432
frequency of A₂ donors, 431
blood transfusion
effect on graft survival rate, 414, 445, 468
effects on lymphocyte reactivity, 453
Fc receptor blocking antibodies, 460
bone histology
in aluminium associated bone disease, 195, 203
in chronic renal failure, 189
in patients with idiopathic hypercalcaemia, 248
button technique for vascular access, 104
calcitriol, treatment of osteodystrophy, 287
calcium carbonate
effect on plasma aluminium concentration, 784
in control of plasma phosphate, 784
calcium metabolism
idiopathic hypercalcaemia, 248
in patients with diabetes mellitus, 221
relationship between aluminium and parathyroid hormone, 244
*Candida* infections, 518
cardiac arrhythmia, during haemodialysis and haemofiltration, 175
cardiovascular
changes during experimental diffusion and ultrafiltration, 275
disease incidence in haemodialysis, 168
function during haemodialysis and haemofiltration, 281
response to fluid removal during haemodialysis, 360
carnitine
absorption in haemodialysis patients, 298
losses during haemodialysis and haemofiltration, 298
therapy in haemodialysis patients, 302
catecholamines, in haemodialysis patients, 270
cell-mediated immunity
in continuous ambulatory peritoneal dialysis, 372, 378
in transplant, 438
see also helper T-cells, mixed leucocyte reaction, monoclonal antibodies, suppressor T-cells, T-cell subsets
 cellulose acetate membrane, 159
cerebrovascular disease, incidence in haemodialysis, 168
children
continuous ambulatory peritoneal dialysis for acute renal failure, 607
continuous ambulatory peritoneal dialysis registry data, 76
causes of renal failure, 70
growth after haemodialysis and transplant, 81
HLA typing in nephrotic syndrome, 602
hypercoagulability in nephrotic syndrome, 597
number receiving treatment, 62, 63
paediatric renal dialysis treatment facilities, 68
registry data, 61
transplant survival, 81
chlorambucil therapy, in membranous glomerulonephritis, 717
cholecalficferol
see vitamin D
cholesterol
high-density lipoprotein values in haemodialysis patients, 168
in haemodialysis and transplant patients, 505
chronic pyelonephritis, bone histology, 190
chronic renal failure
see renal failure, chronic
chorioretinitis, in cytomegalovirus infections, 518
circulating monocytes
complement receptors, 590
function in Henoch-Schönlein syndrome, 590
cirrhosis, mesangial polymeric IgA deposition, 655
coagulation
intravascular in acute renal failure, 325
studies in nephrotic syndrome, 597
complement
activation during haemodialysis and haemofiltration, 159
complement (continued)
deposition in vascular pole, 692
in Henoch-Schönlein syndrome, 590
receptor function in circulating monocytes, 590
computer modelling of dialysis
disequilibrium syndrome, 360
Concanavalin-A
proliferative response, 453
suppressor cells, 669
continuous ambulatory peritoneal dialysis
carnitine losses, 298
causes for abandonment, 36
cell-mediated immunity, 372, 378
effect of blood glucose, 215
effect on hypertension, 215
effect on residual renal function, 397
effect on systemic lupus erythematosus, 378

evolution of diabetic retinopathy, 215
immunological aspects, 378
in children with acute renal failure, 607
incidence of peritonitis, 388
incidence of peritonitis in diabetic patients, 215
in insulin dependent diabetes, 215
in-line bacteriological filter, 388
integrated with haemodialysis, 380
life table analysis of peritonitis risk, 392
number of patients treated 1981, 12
outcome of transplant, 20
peritonitis, 215, 388, 607
protein losses, 397
Registry data, 32
Registry data on children, 76
removal of middle molecules, 403
residual renal function in diabetic patients, 220
single nightly exchange, 380
vitamin D requirements, 220
corticosteroids
see prednisolone
crescentic glomerulonephritis, rheumatoid factor deposition, 686
cryoglobulinaemia, rheumatoid factor deposition, 686
cuprophan membrane, 159
cyclosporin A, 417
cyst formation, in long term haemodialysis patients, 313
cystinosis
 collaborative study on survival, 582
 results of transplant, 588
cytomegalovirus infection
 clinical manifestations in transplant, 558
cytomegalovirus infection (continued)
glomerulopathy, 500, 519
influence on graft survival, 500
in transplant recipients, 516, 558
cytotoxic T-cells, in transplantation, 438
demographic data
adults on haemodialysis and transplant, 5
children on haemodialysis and transplant, 61
dendritic cells, 411
desferrioxamine
 in aluminium associated bone disease, 195, 203
side effects, 201
diabetes mellitus
calcium metabolism, 221
choice of dialysis treatment, 215
effect of continuous ambulatory peritoneal dialysis on retinopathy, 215
evolution of complications following haemodialysis and transplant, 210
insulin requirements in haemodialysis patients, 769
parathyroid hormone, 221
steroid induced after transplantation, 544
survival following transplant, 209
treatment by haemodialysis, 208
treatment by transplant, 208
diary
 see acetate and bicarbonate dialysis
dialyser membranes, 159
 see also cellulose acetate, cuprophan, polycrylonitrile
dialyser re-use, 166
dialysis
 see continuous ambulatory peritoneal dialysis, haemodialysis and peritoneal dialysis
dialysis disequilibrium syndrome
bicarbonate and acetate dialysis, 351
computer modelling, 360
dialysis encephalopathy
progression after transplant, 201
response to desferrioxamine, 206
diet
effect on growth, 84
low nitrogen supplementation in uraemia, 773
disseminated intravascular coagulation, in acute renal failure, 325
diuretic therapy, increased azotaemia in chronic renal failure, 744
donor kidneys
er vascular anomalies, 477
vascular repair prior to transplant, 477
dopamine, use in acute renal failure, 319
DR antigens, in transplantation, 408, 464

echocardiography, evaluation of left ventricular function during haemodialysis and haemofiltration, 281
echotomography, in assessment of arteriovenous fistulae, 238
EDTA Registry Report combined report, 4
paediatric report, 61
electroencephalogram monitoring, during acetate and bicarbonate dialysis, 351
encephalopathy, Registry data, 45
enhancing antibodies, 411
epinephrine
see adrenaline
Epstein-Barr virus infection, 519
E-rosette forming cells
inhibition by B-cell antibodies, 460
in mesangiocapillary glomerulonephritis, 800
in minimal change glomerulonephritis and focal glomerulosclerosis, 677
erthrocyte insulin receptors, in uraemia, 763
erthropoietin, relationship to haemoglobin in long term haemodialysis patients, 313
essential amino acids, supplementation in uraemia, 773
exchangeable sodium, in hypertension, 697

Fc receptors
blocking antibodies after blood transfusion, 460
function in Henoch-Schönlein syndrome, 590
fibrinolysis, inhibition in experimental acute renal failure, 704
fine needle aspiration
in diagnosis of graft rejection, 495
in diagnosis of hyperparathyroidism, 293
focal glomerulosclerosis
changes in renal tubular function, 679
HLA typing, 602
immunoglobulin production, 673
Registry data, 72
thromboembolic complications, 597
free fatty acids, in haemodialysis and transplantation, 505
frusemide, in acute renal failure, 319
globulins
see immunoglobulins
glomerular filtration rate, residual during haemodialysis and continuous ambulatory peritoneal dialysis, 397
glomerulonephritis
bone histology, 190
C₃ deposition in vascular pole, 692
changes in T-cell subsets, 635
hereditary non-AIport type, 575
mechanisms of progression, 617
mesangial IgA disease, 663
prostaglandin production and effects on indomethacin, 738
recurrence in transplant, 28
rheumatoid factor deposition, 686
skin biopsy findings in mesangial IgA disease, 663
tubular changes, 679
see also membranous glomerulonephritis, mesangial IgA disease, mesangio-capillary glomerulonephritis, minimal change glomerulonephritis, rapidly progressive glomerulonephritis
glomerulosclerosis, relationship to hypertension, 697
glucagon
effect of artificial beta cell, 769
effect of carnitine treatment, 302
glucocorticoids
see prednisolone
Goodpasture's syndrome
effect of plasma exchange, 733
treatment with pulse steroids and plasma exchange, 726
graft
see transplantation
growth
in haemodialysis children, 81
in transplant children, 81
relationship to dietary intake, 84
growth hormone
effect of artificial beta cell, 769
effect of carnitine treatment, 302
haematuria
biopsy findings, 692
immunofluorescence findings, 692
vascular pole C₃ deposition, 692
haemodiafiltration
haemodynamic changes, 175
haemodialysis (continued)
  peripheral vascular resistance, 177
  polycrylonitrile dialyser, 175
haemodialysis
  acetate dialysis, 160, 334, 340, 351
  autogenous saphenous vein fistulae, 227
  bicarbonate dialysis, 38, 160, 334, 346, 351
  calcitriol in treatment of renal osteodystrophy, 287
  carnitine losses, 298
  changes in erythrocyte insulin binding, 763
chronic liver disease, 153
combined continuous ambulatory peritoneal dialysis and haemodialysis, 380
complement activation, 159
computer modelling of disequilibrium, 360
cyst formation after long term treatment, 313
deaths from myocardial infarction, 52
diagnosis of hyperparathyroidism, 293
discontinuation following blood pressure control, 182
EEG recording during bicarbonate and acetate dialysis, 351
effects on cardiovascular function, 281
effects of carnitine therapy, 302
effect of phosphate control by CaCO₃, 784
effect on residual renal function, 397
excessive weight gain, 43
haemodynamic response to fluid removal, 360
hepatic silicone deposition, 265
hypoxia, 159
idiopathic hypercalcaemia, 248
incidence of atherosclerosis, 168
in patients with diabetic nephropathy, 208
leucopenia, 159
lipid metabolism, 505
muscle ultrastructure, 258
number of patients treated 1981, 12
parathyroid hormone in patients with diabetes mellitus, 221
platelet adrenergic receptors, 270
potassium metabolism, 756
potassium removal and correction of acidosis, 366
pre-transplant matched blood transfusion, 445
pyridoxine therapy, 308
Registry report for 1981, 4

haemodialysis (continued)
  refractile silicone particles, 144, 265
  relationship between aluminium and parathyroid hormone, 244
  relationship between hypotension and acetate, 340
  respiratory response during acetate and bicarbonate dialysis, 334
  re-use of dialysers, 166
  single needle device, 97
  spallation, 143, 265
  vibration sensory threshold as a guide to adequacy of treatment, 253
  water preparation, 45
haemodynamic
  changes during haemodialfiltration, 175
  response to fluid removal during haemodialysis, 360
haemofiltration
  allowing improved nutrition in acute renal failure, 329
carnitine losses, 298
continuous use in acute renal failure, 329
effects on cardiovascular function, 281
effect on complement, 159
number of patients treated 1981, 12, 39
Registry data, 37
sodium balance, 180
haemoglobin, relationship to cyst formation during haemodialysis, 313
haemolytic uraemic syndrome, continuous ambulatory peritoneal dialysis for acute renal failure, 607
helper T-cells
  in glomerulonephritis, 635
  in mesangial IgA disease, 642
see also T-cell subsets
Hench-Schönlein syndrome
  Fc receptor function and prognosis, 590
polymeric IgA deposition, 655
role of immune complexes, 648
treatment with pulse steroids and plasma exchange, 726
hepatic silicone deposition, 143, 265
hepatitis
  see liver disease
hepatitis B
  biopsy findings in haemodialysis patients with elevated alanine aminotransferase, 153
effect of vaccination on mixed lymphocyte reactions, 453
incidence in patients and staff, 52
Hepatitis B (continued)
in transplant patients, 522
possible relationship to rejection, 442
Registry data on immunisation, 52
relationship to hepatocellular
carcinoma, 523
vaccination, 52
hepatitis viruses, in transplant patients.
522
hepato-renal syndrome, treatment by
dopamine and frusemide, 319
hereditary glomerulonephritis, non-
Alport's type, 575
herpes simplex virus, 515, 520
histocompatibility antigens
see HLA
HLA typing
available facilities in Europe, 23
effect of matching on transplant,
408, 464
in focal glomerulosclerosis, 602
in haemodialysis patients with elevated
alanine aminotransferase, 153
in hereditary glomerulonephritis, 581
in membranous glomerulonephritis,
629
in mesangial IgA disease, 665
in minimal lesion glomerulonephritis,
602
in nephrotic syndrome, 602
hypercalcaemia, idiopathic in chronic
renal failure, 248
hyperparathyroidism
in aluminium associated bone disease,
195
diagnosis by fine-needle aspiration
cytology and ultrasonography, 293
prevention by calcitriol, 287
hypertension
effect of continuous ambulatory
peritoneal dialysis, 215
role in progression of glomerular
disease, 623
genesis in glomerulonephritis, 696
malignant, 182
diagnosis and treatment of renovascular
hypertension, 749
following transplant, 566
transluminal angioplasty, 749
hypocaemia, association with bone
histology, 191
hypotension, dialysis induced, 181, 340
hypoxia, occurrence during haem-
dialysis, 159, 334
Idiotypes, specific auto-immunisation in
tolerance induction, 407, 411
immune complexes
IgA containing in mesangial IgA disease,
667
in Henoch-Schönlein syndrome,
590, 648
in mesangial IgA disease, 648
immune modulation, in transplant, 411
immune regulation
in glomerulonephritis, 635
in mesangial IgA disease, 642
immunity, cell-mediated
see cell-mediated immunity
immunisation
anti-idiotypic, 407, 411
hepatitis B, 52, 453
immunoblastic sarcoma, 520
immunofluorescence
in mesangial IgA deposition, 655
in rheumatoid factor deposition, 686
in primary haematuria, 692
to IgA in mesangial IgA disease and
Henoch-Schönlein syndrome, 648
immunoglobulins
IgA
mesangial deposition in glomerular
disease, 655
production by peripheral
mononuclear cells in mesangial
IgA disease, 642
secretion in glomerulonephritis, 673
serum values in mesangial IgA disease,
667
subclasses in Henoch-Schönlein
syndrome, 648
subclasses in mesangial IgA disease,
648, 660, 664
IgG, secretion in glomerulonephritis,
673
IgM
Fc receptor blockade in Henoch-
Schönlein syndrome, 590
IgM secretion in glomerulonephritis,
673
effects of plasma filtration, 540
in focal glomerulosclerosis, 673
in glomerulonephritis, 692
in minimal change glomerulonephritis,
673
immunosuppression
effect of thoracic duct drainage,
488
in treatment of mesangiocapillary
glomerulonephritis, 794
in treatment of rapidly progressive
glomerulonephritis, 724
indomethacin, in nephrotic syndrome,
738
insulin
effect of carnitine treatment, 302
cytosine binding receptors in
urine, 763
requirements in diabetic patients on
haemodialysis, 769
Interleukin-2, 417
intravascular coagulation
in acute renal failure, 703
diagnosis, 704
in nephrotic syndrome, 597, 710
in transplant rejection, 708
intravenous renal arteriography, in
renovascular hypertension, 749

J chain, mesangial deposition in
glomerulonephritis, 655

keto analogues, supplements in
urine, 773

lactate dialysis, left ventricular function,
281
lecithin-cholesterol-acyltransferase,
in haemodialysis and transplant
patients, 505
left ventricular function
see cardiovascular
leptospirosis, plasmapheresis treatment
in acute renal failure, 88
leucopenia, dialysis induced, 159
levamisole, in treatment of nephrotic
syndrome, 800
lipid metabolism
see also cholesterol
carnitine losses during haemodialysis
and haemofiltration, 298
effect of L-carnitine therapy, 302
in haemodialysis patients, 170, 505
in transplant patients, 505
Listeria monocytogenes, 514
liver disease
associated with viral infections,
523
association with silicone,
143, 153, 265
histological findings, 153
liver histology
in haemodialysis patients, 153, 265
in haemodialysis patients exposed to
silicone tubes, 150
in haemodialysis patients with
elevated alanine aminotransferase,
157
lymphocytes
see also T-cell subsets, suppressor
T-cells, mixed lymphocyte
reaction, cell-mediated immunity
effect of blood transfusion on
reactivity, 453
depletion by thoracic duct drainage,
488
lymphocytotoxic antibodies, following
blood transfusion, 445
lymphoma, viral induction, 520

macrophages
function in Henoch-Schönlein
syndrome, 590
in liver biopsies of haemodialysis
patients with elevated alanine
aminotransferase, 153
location of refractile material after
haemodialysis, 265, 143
silicone containing in liver of haemo-
dialysis patients, 149
malignant disease, role of oncogenic
viruses, 516, 520
malignant hypertension, resolution
following haemodialysis, 182
mathematical modelling, urea kinetics, 381
membrane potential, in proximal tubular
cells, 779
membranes
see dialysis membranes
membranous glomerulonephritis
biopsy grading and outcome, 722
changes in renal tubular function, 679
HLA typing, 629
increased proteinuria following steroid
therapy, 790
T-cell subsets, 629
thromboembolic complications, 597
treatment with steroids and
chlorambucil, 717
mesangial IgA disease
association with ankylosing spondylitis,
667
clinical and serological findings, 663
family studies, 645
genesis of hypertension, 696
geographical distribution, 667
immune regulation, 642
polymeric IgA deposition, 655
role of immune complexes, 648
mesangiocapillary glomerulonephritis
T-cell subsets, 669
treatment by plasmapheresis and
immunosuppression, 794
treatment by thymus factor or
levamisole, 800

811
methylprednisolone
see prednisolone
middle molecules, removal by
continuous ambulatory
peritoneal dialysis, 403
minimal change glomerulonephritis
changes in renal tubular function, 679
HLA typing, 602
immunoglobulin production, 673
thromboembolic complications, 597
mixed leucocyte culture
effect of blood transfusion, 453
in HLA identical allografts, 438
monoclonal antibodies
see T-cell subsets
monocytes
see circulating monocytes and
complement
MT antigens, effect of matching on
transplant, 464
muscle histology
effect of carnitine therapy, 302
in patients with uraemia, 258
myocardial infarction
in haemodialysis patients, 52
lipid profiles in haemodialysis
patients, 170
natural killer cells, 417
nephrotic syndrome
effect of indomethacin, 738
HLA phenotypes, 602
hypercoagulability, 597, 710
increased proteinuria following steroid
therapy, 790
prednisone therapy in patients with
membranous glomerulonephritis,
717
role of prostaglandins, 738
treatment by thymus factor or
levamisole, 800
nitrogen balance, in acute renal failure,
138
noradrenaline, plasma values and
hypertension, 697
nutrition, parenteral in acute renal
failure, 131
osteitis fibrosa, incidence in chronic
renal failure, 189
osteodystrophy
see renal osteodystrophy
osteomalacia, in chronic renal failure,
188
oxalic acid, effect of pyridoxine, 308
paediatric patients
see also children
cause of renal failure, 70
renal dialysis treatment facilities, 68
survival statistics, 81
Registry report, 61
papovaviruses, 523
parathyroid hormone
see also hyperparathyroidism
effect of carnitine treatment, 302
effect of phosphate control by CaCO₃, 784
effect of supplemented low nitrogen
diet, 773
in aluminium associated bone disease,
195, 203
influence of aluminium levels, 244
in patients with diabetes mellitus, 221
in patients with idiopathic
hypercalcaemia, 248
response to calcitriol, 287
parenteral nutrition, in acute renal
failure, 131
passenger leucocytes
see dendritic cells
peritoneal clearance
in continuous ambulatory peritoneal
dialysis, 397
in combined haemodialysis and
peritoneal dialysis, 385
peritoneal dialysis, treatment of acute
renal failure in children, 607
peritoneal ultrafiltration, in continuous
ambulatory peritoneal dialysis, 397
peritonitis, prevention using a bacterio-
logical filter, 388
phenytoin, effect on prednisolone
pharmacokinetics, 549
phosphate
effect of CaCO₃, 784
effect of haemofiltration, 176
effect of supplemented low nitrogen
diet, 773
peritoneal clearance, 397
proximal tubular absorption, 779
phospholipids in haemodialysis and
transplant patients, 505
plasma exchange
in acute renal failure, 52
in glomerular disease, 732
in mesangiocapillary glomerulonephritis,
794
in rapidly progressive glomerulonephritis,
724
in transplant rejection, 732
plasma filtration
effect on acute vascular rejection, 536
effect on plasma proteins, 536
plasmapheresis
  see plasma exchange
platelets
  adrenergic receptors in haemodialysis patients, 270
  function in nephrotic syndrome, 597
  trapping during transplant rejection, 529
polyacrylonitrile membrane, 159, 175
polyarteritis nodosa, treatment, 726
polycystic renal disease
  bone histology, 190
Registry data
  combined report, 4
  in children, 61
red cells
  see blood transfusion, erythrocyte
potassium
  effect of beta adrenergic stimulation, 756
  in correction of acidosis, 366
prednisolone
  clearance, 545
  effect of phenytoin, 549
  effect of rifampicin on pharmacokinetics, 552
  effect on proteinuria, 790
  methylprednisolone at transplantation, 482
  methylprednisolone pulse therapy for rapidly progressive glomerulonephritis, 724
pharmacokinetics, 544, 552
protein binding, 552
side effects, 485, 548
therapy in membranous glomerulonephritis, 717
pregnancy, B-cell antibodies, 461
proliferative glomerulonephritis
  changes in renal tubular function, 679
  thromboembolic complications, 597
prostacyclin
  effect on renal plasma flow, 534
  in treatment of transplant rejection, 529
prostaglandins, in nephrotic syndrome, 738
proteinuria
  effect of thymus factor and levamisole, 800
  in progression of glomerulonephritis, 621
  increased during prednisone therapy, 790
proximal myopathy, in aluminium intoxication, 206
proximal tubular function, phosphate kinetics, 779
pyridoxine, effects on plasma oxalic acid, 308
rapidly progressive glomerulonephritis
  effect of plasma exchange, 734
  treatment with pulse therapy and plasma exchange, 724
red cells
  see blood transfusion, erythrocyte
Registry data
  combined report, 4
  in children, 61
rejection
  see also transplantation
  ABO incompatibility, 28, 427
  acute vascular steroid resistant, 536
  aminophylline treatment of steroid resistant cases, 473
  anti-A isoagglutinins in O recipients, 427
  association with cytomegalovirus infection, 558
  diagnosis by fine needle aspiration and urine cytology, 495
  effect of blood transfusion, 445
  effect of methylprednisolone at time of transplantation, 484
  effect of plasma exchange, 732
  effect of prostacyclin therapy, 529
  effect of thoracic duct drainage, 488
  influence of rhesus E antibodies, 436
  in HLA identical grafts, 441
  radiolabelled platelets in diagnosis, 529
  role of intravascular coagulation, 708
  suppressor T-cell loss during treatment, 473
  treatment by plasma filtration, 536
  remnant kidney, glomerular changes, 622
renal arteriography, intravenous in hypertension, 749
renal artery stenosis
  following transplantation, 568
  percutaneous transluminal dilatation, 749
renal failure
  acute
    amino acid therapy, 129
    coagulation studies, 325
    energy requirement, 130
    essential: non essential amino acid requirement, 138
    experimental induced by intravascular coagulation, 703
    haemofiltration treatment, 329
    management with continuous ambulatory peritoneal dialysis, 607
    nitrogen balance, 138
renal failure (continued)
acute (continued)
nitrogen requirement, 137
Registry data, 52
results of plasmapheresis, 52
role of intravascular coagulation, 703
treatment by dopamine and frusemide, 319
urea generation rate, 132
chronic
combined Registry report, 4
combined paediatric report, 61
distribution of modes of treatment, 6
diuretic increased azotaemia, 744
idiopathic hypercalcaemia, 248
incidence of osteomalacia, 188
muscle ultrastructure, 258
potassium metabolism, 756
survival on all modes of therapy, 15
renal function tests
effect of diuretic therapy in chronic
renal failure, 745
in glomerulonephritis, 679
renal osteodystrophy
aluminium, 195, 203
bone aluminium content, 205
controlled trial of calcitriol, 287
in patients with idiopathic
hypercalcaemia, 248
relationship to primary renal disease, 190
treatment with desferrioxamine, 203
renal transplantation
see transplantation, rejection
renal tubule
function in glomerulonephritis, 679
changes in glomerulonephritis, 679
handling of urea, 744
phosphate kinetics, 779
renin
in nephrotic syndrome, 739
relationship to hypertension in
mesangial IgA disease, 696
residual renal function
in continuous ambulatory peritoneal
dialysis, 397
Registry data, 38
respiratory function, during acetate and
bicarbonate dialysis, 334
reticulum cell sarcoma, induction, 520
reverse osmosis water treatment, 45
rheumatoid factor, pathogenesis in
glomerulonephritis, 686
rosette forming cells
E$^+$ in continuous ambulatory peritoneal
dialysis, 373
inhibitory factors in continuous ambula-
atory peritoneal dialysis fluid, 374
scleroderma, case report, 184
silicone
accumulation during dialysis, 143, 153,
265
experimental studies, 151
hepatic deposition, 265
spallation, 143, 153, 265
somatostatin, effect of carnitine therapy,
302
spallation, 143, 153, 265
splenic macrophage
see macrophage
squamous cell carcinoma, induction by
viruses, 523
steroids
see prednisolone
subclavian catheters
see vascular access
suppressor factor, stimulation by
aminophylline, 473
suppressor T-cells, 411
see also T-cell subsets, Concanavalin-A
effect of aminophylline during
transplant rejection, 473
in glomerulonephritis, 635
in HLA identical grafts, 442
in mesangiocapillary
glomerulonephritis, 669
in mesangial IgA disease, 644
in minimal change glomerulonephritis
and focal glomerulosclerosis, 678
transfusion induced, 453
survival
see Registry data
systemic lupus erythematosus
Registry data, 29
rheumatoid factor deposition, 686
treatment by continuous ambulatory
peritoneal dialysis, 378
systemic vascular resistance, changes
during haemodialysis and
haemofiltration, 281
T-cell function, effect of thymus factor
and levamisole, 800
T-cell subsets
effect of thoracic duct drainage, 488
in continuous ambulatory peritoneal
dialysis and haemodialysis
patients, 372
in glomerulonephritis, 635
in membranous glomerulonephritis,
629
in mesangial IgA disease, 642
in mesangiocapillary glomerulo-
nephritis, 669
T-cell subsets (continued)
in minimal change glomerulonephritis
and focal glomerulosclerosis, 673
in transplantation, 418
in viral infections, 518
see also helper T-cells, mixed
lymphocyte culture, monoclonal
antibodies, suppressor T-cells
thoracic duct drainage, effect on graft
survival, 488
thrombosis
detection in arteriovenous fistulae, 238
in autogenous saphenous vein fistulae, 227
in patients with nephrotic syndrome, 597
thymus factor, in treatment of nephrotic
syndrome, 800
tissue typing
see blood transfusion
transluminal angioplasty, in renovascular
hypertension, 749
transplantation
A2 donors to O recipients, 427
across ABO incompatibility, 28
aminophylline in acute rejection, 473
antibody dependent cellular
cytotoxicity, 441
cytomegalovirus infection and
rejection, 558
cytomegalovirus glomerulopathy, 500
detection of rejection by urine
cytology and fine needle aspiration, 495
effect on aluminium associated bone
disease, 196
effect of blood transfusion, 414, 445,
453, 468
effect of DR matching, 408, 464
effect of HLA matched transfusion,
445
effect of HLA, DR and MT matching,
464
effect of length of preceding dialysis,
19
effect on lipid metabolism, 505
effect of steroid dosage, 21
effect of thoracic duct drainage, 488
Fc receptor blocking antibodies, 460
graft rupture, 469
graft survival, 16, 484
graft survival according to attitudes to
tissue typing, 21
graft and patient survival rates after
continuous ambulatory peritoneal
dialysis, 21
incidence of hypertension, 566
transplantation (continued)
incidence of tolerance, 422
influence of blood group antigens, 432
influence of B-cell antibodies, 460
influence of rhesus E antibodies, 436
in patients with diabetic nephropathy,
208
inter-relationship of hypertension and
obesity, 568
methylprednisolone at transplantation,
482
monozygotic twin transplants, 27
non HLA factors in living related
donors, 438
operations performed in 1981, 9, 13
outcome of grafts with multiple vessels,
477
prednisolone pharmacokinetics, 544
recurrence of focal sclerosis in children,
73
recurrence of original disease, 28
Registry report for 1981, 4
rejection in HLA identical grafts, 441
relation between hypertension and
native kidneys, 571
renal artery stenosis, 568
results in cystinosis, 588
role of immunological parameters, 407
survival of third grafts, 23
vascular anomalies in donor kidneys,
477
vibration sensory threshold changes
after grafting, 253
viral infections, 513
see also rejection
triglycerides, in haemodialysis and
transplant patients, 505
see also lipid metabolism
tuberculosis, 552
tumours
see malignant disease
ultrafiltration
cardiovascular changes in uraemic
dogs, 275
effect on complement, 159
ultrasonography, in diagnosis of
hyperparathyroidism, 293
uræmia
altered beta-receptor response in
experimental uræmia, 788
association between osteomalacia
and plasma 25(OH) cholesterol, 188
cardiovascular response to diffusion
and ultrafiltration in dogs, 275
uraemia (continued)
effect on insulin binding receptors, 763
effect of pyridoxine on oxalic acid metabolism, 308
muscle ultrastructure, 258
treatment by supplemented low nitrogen diet, 773
see also renal failure
uraemic nephropathy, vibration sensory threshold, 253
urea generation rate, 381
uric acid, relationship to growth, 85
urine cytology, in diagnosis of graft rejection, 495

vaccination, hepatitis B, 52
varicella, zoster virus, 521
vascular access
arteriovenous grafts, 102
autogenous saphenous vein fistulae, 227
button technique, 104
catheter perforation of vena cava, 125
complications of PTFE grafts, 234
echotomography, 238
femoral vein catheterisation complications, 122
indications, 121
technique, 116
review of methods, 95
vascular access (continued)
secondary procedures, 99
subclavian catheter, 96, 106
vascular calcification, deterioration during CaCO3 treatment, 784
vascular instability, value of combined haemodialysis peritoneal dialysis, 385
ventricular function
see cardiovascular
vibration sensor threshold, indication to adequacy of dialysis, 253
viral infections
association with malignant disease, 514
in transfused transplant recipients, 449
in transplanted patients, 513
role of anti-thymocyte globulin, 516
vitamin D
1,25-dihydroxycholecalciferol long term for renal osteodystrophy, 287
25(OH) cholecalciferol in chronic renal failure, 192
requirement in continuous ambulatory peritoneal dialysis, 220
Wegener's granulomatosis, treatment with pulse steroids and plasma exchange, 726
Zinkernagel hypothesis, 438